- Trials with a EudraCT protocol (15)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
15 result(s) found for: Thyroiditis.
Displaying page 1 of 1.
EudraCT Number: 2007-001107-38 | Sponsor Protocol Number: SESCHI.26371 | Start Date*: 2008-05-26 | |||||||||||
Sponsor Name:Cefak KG | |||||||||||||
Full Title: Dose finding study to investigate efficacy and tolerability of a 6 month oral treatment with selenium in patients with autoimmune thyroiditis: prospective, controlled parallel group study with Cef... | |||||||||||||
Medical condition: Autoimmune thyroiditis (Hashimoto-thyroiditis) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005606-30 | Sponsor Protocol Number: CAM-THY | Start Date*: 2012-04-25 | |||||||||||||||||||||||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge | |||||||||||||||||||||||||||||||||
Full Title: Keratinocyte Growth Factor - promoting thymic reconstitution and preventing autoimmunity after alemtuzumab (Campath-1H) treatment of multiple sclerosis. CAM-THY | |||||||||||||||||||||||||||||||||
Medical condition: This trial will test the efficacy of Kepivance in the prevention of new autoimmune diseases in patients who have multiple sclerosis (MS)who are being treated with alemtuzumab. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-006651-39 | Sponsor Protocol Number: 111103 | Start Date*: 2008-12-22 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase IV, randomized, open-label, controlled, post-licensure study to evaluate the safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix®) when administered intramuscular... | ||
Medical condition: No medical condition will be investigated in this study. The study will follow vaccinated females and collect safety data focussing on autoimmune diseases, pregnancy outcomes and SAEs considered to... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-001377-28 | Sponsor Protocol Number: 27577 | Start Date*: 2008-06-11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Merck Serono International S.A. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosp... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Completed) DE (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) PT (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003506-26 | Sponsor Protocol Number: CI-331-19 | Start Date*: 2020-03-05 | |||||||||||||||||||||
Sponsor Name:Hospital Universitari Son Espases | |||||||||||||||||||||||
Full Title: Determination of Parathyroid Function by Fluorescence With Indocyanine Green (ICG) After Total Thyroidectomy | |||||||||||||||||||||||
Medical condition: Patients undergoing total thyroidectomy with visualization of the parathyroid glands under infrared light after intraoperative intravenous injection of 5 mg of indocyanine green to predict the poss... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000753-22 | Sponsor Protocol Number: TV2/003/06 | Start Date*: 2006-05-04 |
Sponsor Name:Oxford MioMedica UK Ltd. | ||
Full Title: A phase I/II feasability trial to assess the safety, immunological activity and efficacy of TroVax plus interferon alpha in patients with advanced or metastatic renal cell cancer. | ||
Medical condition: Advanced or Metastatic Renal Cell Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-003796-22 | Sponsor Protocol Number: IFCT-1602 | Start Date*: 2017-09-22 | ||||||||||||||||
Sponsor Name:IFCT | ||||||||||||||||||
Full Title: Immunotherapy by Nivolumab after prior Chemotherapy for HIV+ patients with Advanced non-small cell lung cancer (NSCLC): IFCT-CHIVA2 phase IIa trial | ||||||||||||||||||
Medical condition: Advanced non small cell lung cancer in VIH+ patient | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-001246-13 | Sponsor Protocol Number: TV3/001/06 | Start Date*: 2007-01-22 |
Sponsor Name:Oxford BioMedica UK Ltd. | ||
Full Title: Estudio internacional, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos, para investigar si Trovax, añadido al tratamiento estándar de primera linea, prolonga la supervivenci... | ||
Medical condition: Locally advanced or metastatic renal clear cell adenocarcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) DE (Prematurely Ended) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-006220-40 | Sponsor Protocol Number: 2022-0101-01 | Start Date*: 2022-06-30 | ||||||||||||||||||||||||||
Sponsor Name:Hvidovre Hospital, Department of Gynecology | ||||||||||||||||||||||||||||
Full Title: Double-blinded randomized placebo-controlled trial on tacrolimus in women with an euploid pregnancy loss and PCOS and/or thyroid autoimmunity | ||||||||||||||||||||||||||||
Medical condition: Polycystic ovarian syndrome and/or thyroid autoimmunity in combination with an euploid pregnancy loss | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000256-33 | Sponsor Protocol Number: Ra-P-OCD-01 | Start Date*: 2019-06-27 | |||||||||||
Sponsor Name:Uppsala University Hospital | |||||||||||||
Full Title: A randomized, double-blinded, placebo-controlled study of Rituximab in patients with Psychosis and/or Obsessive Compulsive Disorder, with an indication of immune system involvement | |||||||||||||
Medical condition: Obsessive-compulsive disorder (OCD) or Obsessive-compulsive behaviour (OCB) or psychotic disorder (PD) in which there is an indication of immune system involvement. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003524-32 | Sponsor Protocol Number: NEPHENTE | Start Date*: 2023-01-11 | |||||||||||
Sponsor Name:Istituti Clinici Scientifici Maugeri SpA Società Benefit | |||||||||||||
Full Title: Neoadjuvant pembrolizumab in high-risk thyroid cancers (NEPENTHE) | |||||||||||||
Medical condition: High-risk thyroid cancers | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001836-44 | Sponsor Protocol Number: UCL/11/0119 | Start Date*: 2012-06-11 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: A Phase II Trial to Assess the Activity of TroVax® (MVA-5T4) Versus Placebo in Patients with Relapsed Asymptomatic Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | |||||||||||||
Medical condition: Patients with relapsed asymptomatic epithelial ovarian, fallopian tube or primary peritoneal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001941-11 | Sponsor Protocol Number: 2021-1798 | Start Date*: 2021-09-09 | ||||||||||||||||
Sponsor Name:Rijnstate hospital | ||||||||||||||||||
Full Title: Ultrasound-guided radiofrequency ablation versus radioactive iodine as treatment for hyperthyroidism caused by solitary autonomous thyroid nodules. | ||||||||||||||||||
Medical condition: Patients > 18 years with (subclinical) hyperthyroidism caused by a solitary hyperactive thyroid nodules, either as a solitary hyperactive node in an otherwise normal thyroid gland or as a single hy... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005000-36 | Sponsor Protocol Number: VGN-TED-301 | Start Date*: 2022-07-12 | ||||||||||||||||||||||||||
Sponsor Name:VasaraGen, Inc. | ||||||||||||||||||||||||||||
Full Title: A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED) | ||||||||||||||||||||||||||||
Medical condition: Thyroid eye disease (TED) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) IT (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000417-33 | Sponsor Protocol Number: VIB0551.P3.S2 | Start Date*: 2020-09-30 | |||||||||||
Sponsor Name:Viela Bio, Inc./Horizon Therapeutics Ireland DAC | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4 Related Disease | |||||||||||||
Medical condition: Immunoglobulin G4-related disease (IgG4-RD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) HU (Completed) NL (Trial now transitioned) IT (Trial now transitioned) SE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
